ArticleMolecular medicine (Cambridge, Mass.)2026
Label-free optical biomarker for prostate cancer diagnosis.
Article in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundReprogramming of cellular metabolism in cancer leads to changes in the activity of metabolic coenzymes NAD(P)H and FAD which can be used as markers of tumorigenesis and metastasis. NAD(P)H and FAD form coupled redox pair and regulator of mitochondrial energy metabolism. Since NAD(P)H and FAD are endogenous and auto fluorescent, the coupled redox pair can hence be exploited as a reporter for metabolic activity in tumor microenvironment.
methodsWe have developed a 2P-FLIRR assay (2-photon Fluorescence Lifetime based Redox Ratio), a sensitive metabolic optical biomarker for tumor diagnosis in prostate cancer (PCa) patients' tissue sections. We have imaged and used our novel 2P-FLIRR metric which is the ratio of the enzyme-bound fractions of NAD(P)H and FAD to evaluate PCa patients' surgically resected tissue sections. These were PCa adenocarcinomas with different Gleason grades.
resultsIn comparison with conventional H&E histopathology, our 2P-FLIRR assay showed the potential to distinguish tumor-enriched regions from normal prostate tissue in unstained frozen patient tissue sections. Lower FLIRR values were observed to correspond to tumor versus higher FLIRR values to normal prostate.
conclusionThis pilot feasibility study demonstrates that 2P-FLIRR detects metabolic contrast between prostate cancer and normal prostate tissue in frozen human patient tissue sections. Our study identifies for the first time quantitative 2P-FLIRR as a potential sensitive diagnostic optical biomarker for PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.